Pelareorep primes the tumor for checkpoint inhibition therapy by activating the interferon-gamma signaling pathway andtumor inflammation signature in early breast cancer patients – results of the AWARE-1 trial

H. Loghmani, J Gavila, L. Manso, R. Trauger, F. Salvador, T. Pascual, A. Prat, Matt Coffey, T. Heineman